1234 Managing Idiopathic Hypersomnia in a Patient Following Sleeve Gastrectomy

Roma Balbin Uy,Shelley Hershner

DOI: https://doi.org/10.1093/sleep/zsae067.01234

IF: 6.313

2024-04-20

SLEEP

Abstract:Abstract Introduction Sleeve gastrectomy (SG) is a weight loss surgery removing approximately 80% of the stomach1 resulting in a narrower, tubular stomach “sleeve”. It's considered a restrictive procedure wherein weight loss is achieved by limiting the volume of food intake by diminishing the stomach’s capacity. In Roux-en-Y(RYGB), parts of the small intestine is bypassed and the remaining portion is connected to a newly created smaller stomach. By surgically bypassing regions of the small intestine, RYGB limits nutrient absorption leading to weight loss. It’s considered both a restrictive and malabsortive procedure; thus RYGB is associated with more pharmacologic/metabolic concerns compared to SG. Although there is minimal literature comparing drug absorption between SG vs RYGB, some data proposes both SG and RYGB lead to nutrional deficiencies suggesting SG may also be a malabsorptive procedure altering drug pharmacokinetics by increasing transit time, altering gastric pH and reducing bioavailability for extended-release formulations. Report of case(s) A 41-year-old female with past medical history of sleeve gastrectomy is seen for management of idiopathic hypersomnia (IH). IH was confirmed after a polysomnogram ruled out obstructive sleep apnea (OSA). The MSLT revealed a mean sleep latency of 6.8 minutes without SOREMPs, and excluded central causes. She has tried multiple combination of medications: dextroamphetamine and amphetamine immediate (IR) and extended release (XR), modafinil, and armodafinil. Currently, she is taking dextroamphetamine and amphetamine IR 30 mg in the morning and 15 mg in the afternoon and modafinil 200mg in the morning. She reports significant sleepiness 2-3 hours after taking her medications. Conclusion While SG primarily impacts the stomach, it's crucial to note that the procedure can influence drug absorption with effects such as increased drug transit time, and changes in pH. In bariatric surgery patients, utilizing dosage forms that allows drug disintegration, resistant to acidic environments, and has increased bioavailability—such as liquids or even transdermal formulations—may mitigate altered drug absorption. For this patient, we have discussed smaller and more frequent doses of dextroamphetamine and amphetamine IR formulations e.g 20 mg IR every 3-4 hours (maximum 60 mg today daily dose). If this is not effective, calcium, magnesium, potassium & sodium oxybate can be considered. Support (if any)

neurosciences,clinical neurology